Skip to main content
SpringerLink
Log in

Systemically available bone morphogenetic protein two and seven affect bone metabolism

  • Original Paper
  • Published:
International Orthopaedics Aims and scope Submit manuscript

Abstract

Purpose

Bone morphogenetic protein (BMP)-2 and -7 are used in patients with long-bone fractures, nonunions and spinal fusions. It is unknown whether their potential systemic bioavailability following local bone administration might affect skeletal metabolism. To answer this question, we examined effects of systemically administered BMP-2 and -7 on bone in a newly developed rat model with a low level of calciotropic hormones.

Methods

Removal of thyroid and parathyroid glands (TPTx) in rats resulted in a decreased level of calciotropic hormones and subsequent bone loss assessed by micro computed tomography (micro-CT) and measurement of serum bone formation and resorption markers, including osteocalcin, C-telopeptide, osteoprotegerin and receptor activator of nuclear factor kappa-B ligand. Results were complemented with in vitro studies on osteoblast and osteoclast activity by both BMP-2 and -7. The doses used were calculated from published pharmacodynamic studies and bioavailability results from preclinical BMP-2 and -7 studies.

Results

TPTx resulted in bone loss, which was restored by systemic administration of 10–70 μg/kg of BMP-2 and 10–250 μg/kg of BMP-7. BMP-2 showed a higher capacity for enhancing trabecular microarchitecture, whereas BMP-7 augmented trabecular thickness. In vitro experiments revealed that BMP-2 and -7 when uncoupled increased the number and activity of both osteoblasts and osteoclasts.

Conclusions

Surprisingly, both BMP-2 and -7 showed an increased bone volume in an in vivo environment of low calciotropic hormones. Locally administered BMP-2 and -7 from bone devices might become partially available in circulation but will not mediate systemic bone loss.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Vukicevic S, Stavljenic A, Pecina M (1995) Discovery and clinical applications of bone morphogenetic proteins. Eur J Clin Chem Clin Biochem 33:661–671

    CAS  PubMed  Google Scholar 

  2. Jelic M, Pecina M, Haspl M, Kos J, Taylor K, Maticic D, McCartney J, Yin S, Rueger D, Vukicevic S (2001) Regeneration of articular cartilage chondral defects by osteogenic protein-1 (bone morphogenetic protein-7) in sheep. Growth Factors 19:101–113

    Article  CAS  PubMed  Google Scholar 

  3. Jelic M, Grgurevic L, Vukicevic S (2014) Scaffold-free endogenous healing of the articular cartilage lesion. In: Doral MN and Karlsson J (eds) Sport injuries: prevention, diagnosis, treatment and rehabilitation, 2nd ed. Springer-Verlag

  4. Pecina M, Jelic M, Martinovic S, Haspl M, Vukicevic S (2002) Articular cartilage repair: the role of bone morphogenetic proteins. Int Orthop 26:131–136

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Govender S, Csimma C, Genant HK, Valentin-Orpan A, BMP-2 Evaluation in surgery for Tibial Trauma (BESTT) study group et al (2002) Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of 450 patients. J Bone Joint Surg Am 84-A:2123–2134

    PubMed  Google Scholar 

  6. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S (2001) Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 83-A:151–158

    Google Scholar 

  7. Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R, Helfand M (2013) Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spinal fusion: a systematic review and meta-analysis. Ann Intern Med 158:890–902

    Article  PubMed  Google Scholar 

  8. Simmonds MC, Brown JV, Heirs MK, Higgins JP, Mannion RJ, Rodgers MA, Stewart LA (2013) Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med 158:877–889

    Article  PubMed  Google Scholar 

  9. Ekrol I, Hajducka C, Court-Brown C, McQueen MM (2008) A comparison of rhBMP-7 (OP-1) and autogenous graft for metaphyseal defects after osteotomy of distal radius. Injury 39:S73–S82

    Article  PubMed  Google Scholar 

  10. McGee MA, Findlay DM, Howie DW, Carbone A, Ward P, Stamenkov R, Page TT, Bruce WJ, Wildenauer CI, Toth C (2004) The use of OP-1 in femoral impaction grafting in a sheep model. J Orthop Res 22:1008–1015

    Article  CAS  PubMed  Google Scholar 

  11. Peric M, Dumic-Cule I, Grcevic D, Matijasic M, Verbanac D, Grgurevic L, Trkulja V, Bagi C, Vukicevic S (2014) The rational use of animal models in the evaluation of novel bone regenerative therapies. Bone. doi:10.1016/j.bone.2014.07.010

  12. Dumic-Cule I, Draca N, Luetic AT, Jezek D, Rogic D, Grgurevic L, Vukicevic S (2014) TSH prevents bone resorption and with calcitriol synergistically stimulates bone formation in rats with low levels of calciotropic hormones. Horm Metab Res 46:305–312

    Article  CAS  PubMed  Google Scholar 

  13. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression dana using real-time quantitative PCR and the 2(−Delta Delta C(T)). Methods 25:402–408

    Article  CAS  PubMed  Google Scholar 

  14. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281

    Article  CAS  PubMed  Google Scholar 

  15. Vukicevic S, Oppermann H, Verbanac D, Jankolija M, Popek I, Curak J, Brkljacic J, Pauk M, Erjavec I, Francetic I, Dumic-Cule I, Jelic M, Durdevic D, Vlahovic T, Novak R, Kufner V, Bordukalo Niksic T, Kozlovic M, Banic Tomisic Z, Bubic-Spoljar J, Bastalic I, Vikic-Topic S, Peric M, Pecina M, Grgurevic L (2014) The clinical use of bone morphogenetic proteins revisited: a novel biocompatible carrier device OSTEOGROW for bone healing. Int Orthop 38:635–647

    Article  PubMed  Google Scholar 

  16. Suzuki J, Otsuka F, Takeda M, Kenichi I, Tomoko M, Mimura Y, Ogura T, Doihara H, Makino H (2005) Functional role of the bone morphogenetic protein system in thyrotropin signaling in porcine thyroid cells. Biochem Biophys Res Commun 327:1124–1130

    Article  CAS  PubMed  Google Scholar 

  17. Kamiya N, Ye L, Kobayashi T, Lucas DJ, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y (2008) Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. J Bone Miner Res 23:2007–2017

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342

    Article  CAS  PubMed  Google Scholar 

  19. Sanchez-Fernandez MA, Gallois A, Riedl T, Jurdic P, Hoflack B (2008) Osteoclasts control osteoblast chemotaxis via PDGF-BB/PDGF receptor beta signaling. PLoS One 3:e3537

    Article  PubMed Central  PubMed  Google Scholar 

  20. Simic P, Culej JB, Orlic I, Grgurevic L, Draca N, Spaventi R, Vukicevic S (2006) Systemically administered bone morphogenetic protein-6 restores bone in aged ovariectomized rats by increasing bone formation and suppressing bone resorption. J Biol Chem 281:25509–25521

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by the Croatian Science Foundation, project 08/5 BONE6-BIS. We acknowledge Djurdja Car and Mirjana Marija Renic for providing animal care in all rat studies.

Author information

Authors and Affiliations

  1. Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, School of Medicine, University of Zagreb, Šalata 11, Zagreb, 10000, HR, Croatia

    Ivo Dumic-Cule, Jelena Brkljacic, Tatjana Bordukalo Niksic, Ana Tikvica Luetic, Natasa Draca, Vera Kufner, Lovorka Grgurevic & Slobodan Vukicevic

  2. Clinical Institute of Laboratory Diagnosis, University Hospital Centre Zagreb, Zagreb, Croatia

    Dunja Rogic

  3. Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia

    Vladimir Trkulja

Authors
  1. Ivo Dumic-Cule
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jelena Brkljacic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dunja Rogic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tatjana Bordukalo Niksic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ana Tikvica Luetic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Natasa Draca
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vera Kufner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Vladimir Trkulja
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lovorka Grgurevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Slobodan Vukicevic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Slobodan Vukicevic.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dumic-Cule, I., Brkljacic, J., Rogic, D. et al. Systemically available bone morphogenetic protein two and seven affect bone metabolism. International Orthopaedics (SICOT) 38, 1979–1985 (2014). https://doi.org/10.1007/s00264-014-2425-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00264-014-2425-8

Keywords

Search

Navigation